Rose Nabatanzi1, Lois Bayigga2, Isaac Ssinabulya3, Agnes Kiragga4, Andrew Kambugu5, Joseph Olobo6, Moses Joloba7, Moses R Kamya8, Harriet Mayanja-Kizza9, Damalie Nakanjako10. 1. Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. Electronic address: rosemagala@yahoo.com. 2. Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. Electronic address: baylois@gmail.com. 3. Department of Internal Medicine, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda. Electronic address: ssinabulyaisaac@gmail.com. 4. Infectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: akiragga@idi.co.ug. 5. Infectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: akambugu@idi.co.ug. 6. Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. Electronic address: jolobo@yahoo.co.uk. 7. Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda; Department of Internal Medicine, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda; Infectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: moses.joloba@case.edu. 8. Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda; Department of Internal Medicine, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda; Infectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: mkamya@infocom.co.ug. 9. Infectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: hmk@chs.mak.ac.ug. 10. Department of Internal Medicine, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda; Infectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: dnakanjako@gmail.com.
Abstract
BACKGROUND: CD4 counts guide antiretroviral therapy (ART) initiation and prophylaxis for opportunistic infections. It is unclear whether normal CD4 counts translate to normalized immune responses among ART-treated adults. We compared antigen-specific CD4 T-cell immune responses among ART-treated adults with CD4≥500cells/μl, optimal immune responders (O-IR), and their age-matched healthy HIV-negative counterparts. METHODS: In a sample-based case-control study, cryopreserved peripheral blood mononuclear cells from 15 O-IR after 7 years of ART and 15 healthy controls, were analyzed for CD4+ T-cell proliferation using CFSE dye and cytokine production. RESULTS: CD4 T-cell proliferation, upon stimulation with PPD and pneumococcal polysaccharide antigen, was lower among O-IR relative to HIV-negative controls; p=0.016 and p=0.016 respectively. CD4 T-cell production of IL-2 was lower among O-IR relative to HIV-negative control p=0.002. CD4 T-cell proliferation upon stimulation with SEB and CMV antigens was similar among O-IR and HIV-negative controls p=0.971 and p=0.480, respectively, and so was IL-4 and IFN γ production; p=0.528 and p=0.892, respectively. CONCLUSION: Seven years of suppressive ART caused partial CD4 T-cell function recovery in an African HIV treatment cohort, despite restoration of CD4 T-cell counts to levels≥500cells/μl. The role innate immunity in the recovery of immune function during long-term ART should be investigated to guide decisions on continued prophylaxis against opportunistic infections.
BACKGROUND:CD4 counts guide antiretroviral therapy (ART) initiation and prophylaxis for opportunistic infections. It is unclear whether normal CD4 counts translate to normalized immune responses among ART-treated adults. We compared antigen-specific CD4 T-cell immune responses among ART-treated adults with CD4≥500cells/μl, optimal immune responders (O-IR), and their age-matched healthy HIV-negative counterparts. METHODS: In a sample-based case-control study, cryopreserved peripheral blood mononuclear cells from 15 O-IR after 7 years of ART and 15 healthy controls, were analyzed for CD4+ T-cell proliferation using CFSE dye and cytokine production. RESULTS:CD4 T-cell proliferation, upon stimulation with PPD and pneumococcalpolysaccharide antigen, was lower among O-IR relative to HIV-negative controls; p=0.016 and p=0.016 respectively. CD4 T-cell production of IL-2 was lower among O-IR relative to HIV-negative control p=0.002. CD4 T-cell proliferation upon stimulation with SEB and CMV antigens was similar among O-IR and HIV-negative controls p=0.971 and p=0.480, respectively, and so was IL-4 and IFN γ production; p=0.528 and p=0.892, respectively. CONCLUSION: Seven years of suppressive ART caused partial CD4 T-cell function recovery in an African HIV treatment cohort, despite restoration of CD4 T-cell counts to levels≥500cells/μl. The role innate immunity in the recovery of immune function during long-term ART should be investigated to guide decisions on continued prophylaxis against opportunistic infections.
Authors: Sergei Spitsin; Nancy B Tustin; Eric Riedel; Richard Tustin; Jennifer B Murray; Lauren M Peck; Mohammad Khan; Joseph Quinn; Steven D Douglas Journal: Clin Vaccine Immunol Date: 2012-03-21
Authors: Christine A Jansen; Iris M De Cuyper; Radjin Steingrover; Suzanne Jurriaans; Sanjay U C Sankatsing; Jan M Prins; Joep M A Lange; Debbie van Baarle; Frank Miedema Journal: AIDS Date: 2005-07-22 Impact factor: 4.177
Authors: B Ledergerber; A Mocroft; P Reiss; H Furrer; O Kirk; M Bickel; C Uberti-Foppa; C Pradier; A D'Arminio Monforte; M M Schneider; J D Lundgren Journal: N Engl J Med Date: 2001-01-18 Impact factor: 91.245
Authors: Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja Journal: N Engl J Med Date: 2013-01-17 Impact factor: 91.245
Authors: Hernan Valdez; Elizabeth Connick; Kimberly Y Smith; Michael M Lederman; Ronald J Bosch; Ryung S Kim; Marty St Clair; Daniel R Kuritzkes; Harold Kessler; Lawrence Fox; Michelle Blanchard-Vargas; Alan Landay Journal: AIDS Date: 2002-09-27 Impact factor: 4.177
Authors: Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Sarah J Glennie; Enoch Sepako; David Mzinza; Visopo Harawa; David J C Miles; Kondwani C Jambo; Stephen B Gordon; Neil A Williams; Robert S Heyderman Journal: PLoS One Date: 2011-09-27 Impact factor: 3.240
Authors: Rose Nabatanzi; Stephen Cose; Moses Joloba; Sarah Rowland Jones; Damalie Nakanjako Journal: AIDS Res Ther Date: 2018-03-15 Impact factor: 2.250